COSENTYX Emerging Drug Insight and Market Forecast - 2032

COSENTYX Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about COSENTYX for Hidradenitis Suppurativa (HS) in the 7MM. A detailed picture of the COSENTYX for Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the COSENTYX for Hidradenitis Suppurativa. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the COSENTYX market forecast, analysis for Hidradenitis Suppurativa in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hidradenitis Suppurativa.

Drug Summary

COSENTYX (secukinumab), marketed by Novartis, is an IL-17A monoclonal antibody that selectively binds to IL-17A and inhibits Interleukin-17A, and IL-17 promotes neutrophil activities. These cytokines act on many different cell types and defend against different extracellular pathogens that cause fungal or bacterial infections. This product is approved for several indications, such as plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. However, the company is investigating this product for the treatment of hidradenitis suppurativa patients. This therapeutic molecule is administered by the subcutaneous route.

In February 2023 - Novartis announced that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating COSENTYX (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS). In two of the largest Phase III trials conducted in HS, COSENTYX treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% of patients achieving a HS Clinical Response (HiSCR) measure at Week 52.

The results have been submitted to regulatory authorities in Europe and the United States, and decisions are expected in 2023. If approved, COSENTYX will be the first and only interleukin-17 inhibitor for the treatment of moderate-to-severe HS.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the COSENTYX description, mechanism of action, dosage and administration, research and development activities in Hidradenitis Suppurativa.
• Elaborated details on COSENTYX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the COSENTYX research and development activity in Hidradenitis Suppurativa in detail across the United States, Europe, and Japan.
• The report also covers the patent's information with expiry timeline around COSENTYX.
• The report contains forecasted sales of COSENTYX for Hidradenitis Suppurativa till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Hidradenitis Suppurativa.
• The report also features the SWOT analysis with analyst views for COSENTYX in Hidradenitis Suppurativa.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

COSENTYX Analytical Perspective

In-depth COSENTYX Market Assessment

This report provides a detailed market assessment of COSENTYX in Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

COSENTYX Clinical Assessment

The report provides the clinical trials information of COSENTYX in Hidradenitis Suppurativa covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Hidradenitis Suppurativa is set to change due to extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence COSENTYX dominance.
• Other emerging products for Hidradenitis Suppurativa are expected to give tough market competition to COSENTYX and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of COSENTYX in Hidradenitis Suppurativa.
• This in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the COSENTYX in Hidradenitis Suppurativa.

 

Key Questions Answered

• What is the product type, route of administration, and mechanism of action of COSENTYX?
• What is the clinical trial status of the study related to COSENTYX in Hidradenitis Suppurativa and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the COSENTYX development?
• What are the key designations that have been granted to COSENTYX for Hidradenitis Suppurativa?
• What is the forecasted market scenario of COSENTYX for Hidradenitis Suppurativa?
• What are the forecasted sales of COSENTYX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Hidradenitis Suppurativa and how are they giving competition to COSENTYX for Hidradenitis Suppurativa?
• Which are the late-stage emerging therapies under development for the treatment of Hidradenitis Suppurativa?

This product will be delivered within 2 business days.